Kiniksa’s ARCALYST keeps spreading to more patients and earlier use, helped by easier access through insurance changes, which could push growth beyond what many expect. But the story depends heavily on one drug, and new rivals, pricing pushback, and big ongoing spending could quickly change the outlook.Read more
Kiniksa leans heavily on one key medicine, and that makes it vulnerable if rivals, cheaper look-alikes, or tougher insurance rules start to bite before newer treatments are ready. See what could keep demand strong—and what might slow the path to turning its research pipeline into a more balanced business.Read more
Kiniksa leans heavily on ARCALYST, and the big question is whether it can keep expanding use of the drug as doctors start treating patients earlier and more widely. New drug candidates and a strong cash position could reduce its one-product risk over time, but competition, pricing pressure, and U.S.-focused exposure could quickly change the story.Read more
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
